BiotechTube
Home/Galderma Group/Baldo Scassellati Sforzolini
BS

Baldo Scassellati Sforzolini

Global Head of Research & Development

Galderma Group

Therapeutic Areas

DermatologyAesthetic Medicine

Galderma Group Pipeline

DrugIndicationPhase
NemolizumabModerate-to-Severe Atopic Dermatitis (Adults/Adolescents)Approved/Filed
RelabotulinumtoxinA (QM1114)Aesthetic IndicationsPhase 3
Bimatoprost Sustained-ReleaseGlaucoma/Ocular HypertensionPhase 3
CD07805/47Inflammatory Dermatoses (e.g., Psoriasis)Phase 2
GM-502Androgenetic AlopeciaPhase 2
GM-503Acne VulgarisPhase 1

Leadership Team at Galderma Group

FØ
Flemming Ørnskov
Chief Executive Officer
AM
Andrew McConaghie
Chief Financial Officer
BF
Brett Feinstein
Chief Commercial Officer
HL
Hervé Lilliu
Chairman of the Board
View full Galderma Group profile